LY3337641/HM71224

$690M deal in peril after Lilly ends mid-stage studies
Biopharma Dive
Wed, 02/21/18 - 09:43 am
Eli Lilly
clinical trials
rheumatoid arthritis
Btk inhibitors
Hanmi Pharmaceutical
LY3337641/HM71224